Integral Health Asset Management, LLC Historic Quarter Change: Foreign Stocks, New

Integral Health Asset Management, LLC historic quarter change: Foreign Stocks, New

In share positions in stocks (depositary receipts and foreign shares traded over the counter), over 10 quarters from 2023-12-31 to 2026-06-30, Integral Health Asset Management, LLC opened 17 positions, added to 10, reduced 8 and sold out of 15.

Q2 2026: Stock NVO; Country of operation —; Class ADR; Shares before 0.
Q2 2026: Stock BNTX; Country of operation —; Class SPONSORED ADS; Shares before 0.
Q1 2026: Stock IMCR; Country of operation —; Class ADS; Shares before 0.
Q1 2026: Stock IVA; Country of operation —; Class ADS; Shares before 0.

Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1773206), 10 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-14); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-15); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-17); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-14); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-14); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-15); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-14); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-14); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-14); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-15). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2019-12-31.

Quarter	Stock	Country of operation	Class	Shares after	Share change	Value before	Value after	Value change	Filed
Q2 2026	NVO NOVO-NORDISK A S		ADR	600,000	+600,000	$0	$28,764,000	+$28,764,000	2026-08-14
Q2 2026	BNTX BIONTECH SE		SPONSORED ADS	50,000	+50,000	$0	$4,652,500	+$4,652,500	2026-08-14
Q1 2026	IMCR IMMUNOCORE HLDGS PLC		ADS	100,000	+100,000	$0	$3,015,000	+$3,015,000	2026-05-15
Q1 2026	IVA INVENTIVA SA		ADS	400,000	+400,000	$0	$2,220,000	+$2,220,000	2026-05-15
Q4 2025	TEVA TEVA PHARMACEUTICAL INDS LTD		SPONSORED ADS	1,000,000	+1,000,000	$0	$31,210,000	+$31,210,000	2026-02-17
Q4 2025	GPCR STRUCTURE THERAPEUTICS INC	United States	SPONSORED ADS	50,000	+50,000	$0	$3,477,500	+$3,477,500	2026-02-17
Q1 2025	NVS NOVARTIS AG		SPONSORED ADR	250,000	+250,000	$0	$27,870,000	+$27,870,000	2025-05-15
Q1 2025	VRNA VERONA PHARMA PLC		SPONSORED ADS	115,000	+115,000	$0	$7,301,350	+$7,301,350	2025-05-15
Q4 2024	TEVA TEVA PHARMACEUTICAL INDS LTD		SPONSORED ADS	500,000	+500,000	$0	$11,020,000	+$11,020,000	2025-02-14
Q4 2024	SLN SILENCE THERAPEUTICS PLC		ADS	200,000	+200,000	$0	$1,376,000	+$1,376,000	2025-02-14
Q4 2024	CMPS COMPASS PATHWAYS PLC		SPONSORED ADS	200,000	+200,000	$0	$756,000	+$756,000	2025-02-14
Q3 2024	FMS FRESENIUS MEDICAL CARE AG		SPONSORED ADR	450,000	+450,000	$0	$9,585,000	+$9,585,000	2024-11-14
Q3 2024	BNTX BIONTECH SE		SPONSORED ADS	50,000	+50,000	$0	$5,938,500	+$5,938,500	2024-11-14
Q2 2024	SNY SANOFI		SPONSORED ADR	200,000	+200,000	$0	$9,704,000	+$9,704,000	2024-08-14
Q1 2024	ONC BEIGENE LTD		SPONSORED ADR	40,000	+40,000	$0	$6,255,600	+$6,255,600	2024-05-15
Q1 2024	AUTL AUTOLUS THERAPEUTICS PLC		SPON ADS	500,000	+500,000	$0	$3,190,000	+$3,190,000	2024-05-15
Q1 2024	MREO MEREO BIOPHARMA GROUP PLC		SPON ADS	950,000	+950,000	$0	$3,135,000	+$3,135,000	2024-05-15

Similar Firms

Firm Name	Country	13F Value	Holdings
Klingman & Associates, LLC	United States	$2.089B	332
CSS LLC/IL	United States	$2.088B	961
Analog Century Management LP	United States	$2.094B	25
NEW SOUTH CAPITAL MANAGEMENT INC	United States	$2.087B	75
Aventail Capital Group, LP	United States	$2.086B	170
NLB Skladi, upravljanje premozenja, d.o.o.		$2.086B	335
Third Point LLC	United States	$2.083B	33
Avantyr Capital Partners, LP	United States	$2.082B	22
TruWealth Advisors, LLC	United States	$2.081B	182
Avala Global LP	United States	$2.081B	22